Viewing Study NCT00161811



Ignite Creation Date: 2024-05-05 @ 11:53 AM
Last Modification Date: 2024-10-26 @ 9:15 AM
Study NCT ID: NCT00161811
Status: COMPLETED
Last Update Posted: 2015-10-09
First Post: 2005-09-08

Brief Title: Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 20042005
Sponsor: Resilience Government Services Inc
Organization: Resilience Government Services Inc

Study Overview

Official Title: Single-blind Randomized Controlled Phase IIIII Study to Investigate the Immunogenicity and Safety After a Single Vaccination With Three Different Lots of an Inactivated Influenza Vaccine Whole Virion Vero Cell-derived in Comparison to a Licensed Egg Derived Influenza Vaccine for Season 20042005
Status: COMPLETED
Status Verified Date: 2006-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine whole virion Vero cell-derived at Day 21 and Day 180 after vaccination
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
EudraCT Number 2004-001374-34 None None None